text:
JP2006515065A - Fluorescence sequence reading - Google Patents
Fluorescence sequence reading Download PDF
ウェブ,ロバート,エイチ.
モンタグ,ジーン,アイ.
ディシジョン バイオマーカーズ インコーポレイテッド
Family has litigation
2003-08-18 Application filed by ディシジョン バイオマーカーズ インコーポレイテッド filed Critical ディシジョン バイオマーカーズ インコーポレイテッド
2013-05-02 First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31892097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2006515065(A) "Global patent litigation dataset" by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
2020-01-20 Application status is Pending legal-status Critical
G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
G01N21/64—Fluorescence; Phosphorescence
G01N21/645—Specially adapted constructive features of fluorimeters
G01N21/6452—Individual samples arranged in a regular 2D-array, e.g. multiwell plates
G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
G01N21/6456—Spatial resolved fluorescence measurements; Imaging
G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
B01J2219/00277—Apparatus
B01J2219/00279—Features relating to reactor vessels
B01J2219/00306—Reactor vessels in a multiple arrangement
B01J2219/00313—Reactor vessels in a multiple arrangement the reactor vessels being formed by arrays of wells in blocks
B01J2219/00315—Microtiter plates
B01J2219/00351—Means for dispensing and evacuation of reagents
B01J2219/00387—Applications using probes
B01J2219/00497—Features relating to the solid phase supports
B01J2219/00527—Sheets
B01J2219/00533—Sheets essentially rectangular
B01J2219/00583—Features relative to the processes being carried out
B01J2219/00603—Making arrays on substantially continuous surfaces
B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
B01J2219/00612—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports the surface being inorganic
B01J2219/00632—Introduction of reactive groups to the surface
B01J2219/00637—Introduction of reactive groups to the surface by coating it with another layer
B01J2219/00639—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium
B01J2219/00641—Making arrays on substantially continuous surfaces the compounds being trapped in or bound to a porous medium the porous medium being continuous, e.g. porous oxide substrates
B01J2219/00718—Type of compounds synthesised
B01J2219/0072—Organic compounds
B01J2219/00722—Nucleotides
B01J2219/00725—Peptides
B01J2219/0074—Biological products
C40—COMBINATORIAL TECHNOLOGY
C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICO LIBRARIES
C40B40/00—Libraries per se, e.g. arrays, mixtures
C40B40/04—Libraries containing only organic compounds
C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
C40B60/00—Apparatus specially adapted for use in combinatorial chemistry or with libraries
C40B60/14—Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries
G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
G01N21/27—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection ; circuits for computing concentration
G01N21/274—Calibration, base line adjustment, drift correction
Reading the fluorescent array (103) in a clinical setting consists of a reader (110) constructed with dark field illumination of the array and an imaging dimension (Di) of the same size as the fluorescent array dimension (Do), preferably This is possible using mapping of the array image onto the solid state sensor array (146) using the reduced image. Using high intensity illumination, the non-uniformity is compensated by normalization using the array's own brightness calibration feature (164) detected during the imaging period of the array. High intensity light emitting diodes (122, 132, 402, 404), preferably used for traffic lights, are used for array excitation, preferably this excitation is introduced into the array via a solid internal reflection homogenizer (130). A medium depth of field collection and imaging optics allows substantial light collection with NA in the range of 0.30 to 0.60, preferably in the range of 0.4 to 0.55. The resulting relatively large depth of field is compensated in some advantageous cases by absorbing light that tends to travel beyond the spot to be imaged or that may generate noise fluorescence, eg, the substrate (302). Absorption is caused by an opaque metal oxide coating (304), preferably interposed between the ultra-thin substrate on which the array lies and a thicker glass or other rigid support (306). For clinical purposes, the sequence consists of less than 1000 spots suitable for proteins, and in one example, the sequence is less than 500 spots. A relatively large spot size is used, for example, a diameter on the order of at least 80 or 100 microns, or preferably above, using a spot of 150 or 300 microns. This type of spot resolution for at least 50 pixels on a solid state detector allows proper binning and other operations leading to high accuracy results. New methods of analysis and diagnosis, such as cancer diagnosis, use a reader to detect markers associated with a disease, such as ovarian cancer.
The field to which this disclosure relates is clinical microarray technology, such as clinical research and clinical diagnosis.
Fine array technology has evolved over the past decade. It is used to investigate biomolecules, especially nucleic acid and amino acid materials. Effective use has been made by genome elucidation and drug discovery techniques. Although it has been predicted that the technology will ultimately evolve and enable practical applications for clinical, eg clinical research and clinical diagnostics, the prospects seemed far away. This was simply a long-term hope because of the very high cost of the equipment needed, the time required to perform the analysis, and a high level of experience and skill.
As is well known, if the appropriate components are present, the microarray is used to create a tagged or marked feature field or a different analyte spot. Marking has often been by radioisotope tags, but fluorescent tags have become widely used for several reasons, including the convenience of being able to process the material and not requiring safety considerations. In general, it is desirable to represent the analysis by a whole image of the sequence or a small set of related sequences.
Fluorescence microarray readers are key to array usage. The reader records the presence and extent of fluorescence in each feature precisely located in the array in response to exposure to photoexcitation. After careful consideration of various configurations related to reader design, a few successful techniques have found acceptance. These have required not only various optical systems and software, but also precise and costly mechanical development. In one case, a high-speed oscillation scanning arm moves a small lens that reads one pixel at a time in a single coordinate in a confocal configuration, while the image of the array in the other coordinate is accurately scanned using a microscope stage. Develop with a step-by-step advance. (This stage is a device that produces precise motion with micron or sub-micron accuracy and is expensive to manufacture in addition to other components). In this approach, software is used to collect images from a wide array of concentrated pixels. Another technique is to electronically merge or "stitch" the entire array of images by moving the precision steps between each successive enlarged image of a small portion of the array and the subsequent small field image frame. Has generated a large, enlarged view of a portion of the entire array. Previous proposals or considerations using solid state array sensors that image the entire array with a single acquisition are a practical solution to the entire set of problems, ie, simultaneously achieving high precision and high speed operation at a reasonable cost. Did not bring. Over time and as reader production increases, the cost of these image processing systems, which work with concise design, can range from hundreds of thousands of current US dollars to just under 100,000 dollars in some cases. Has been reduced. However, the outlook seems to be far away until mass production will allow reader prices to approach prices that can be attractive for clinical use, for example, less than US $ 25,000. It was.
In general, it has been found that readers that can be used in actual clinical applications, i.e. clinical research, clinical diagnosis and monitoring, can be used in specific combinations, with some restrictions, and in other fields. It can be implemented using the publicly available components that have been issued. Embodiments can meet stringent low cost requirements for clinical readers with the need for considerable speed and ease of operation, while achieving the high level of accuracy required for medical applications.
The basic reader structure should utilize dark field illumination, for example, light that reaches a two-dimensional array at an acute angle of 20-50 degrees, which is a solid state detection array such as a CCD sensor or CMOS array. It has been found that for the above two-dimensional imaging, the mapping on the array must be matched in such a way that it is a measure of the same magnitude as the array of biological features. Imaging is made at right angles to the biological array plane and has a moderate numerical aperture (NA), preferably NA = 0.3 to 0.6, here preferably NA = 0.4 to 0.5. Achieved using an optically focused imaging system having a range of five. Embodiments within these constraints can image the entire array within a single frame without moving or stitching the components of the array. Preferably, the cooperation of features in the device with further new improvements to be accounted for can compensate for this type of configuration, i.e. the inherent limitations of its relatively large depth of field, such as high-intensity diodes, etc. It will be appreciated that the non-uniform illumination can be compensated when using suitable, relatively inexpensive illumination. The resulting device can be made available to clinicians at the cost of making the system and technology practical because of its simplicity and lack of precision moving parts or expensive optics. Thus, practical high-speed clinical imaging is possible even today, and this can provide significant benefits for medical care and patient care.
According to one aspect of the present invention, an array reading suitable for clinical purposes of reading a two-dimensional array (103) of features on a flat substrate, said features carrying a photosensitive marker, the marker being capable of emitting light upon excitation. An illumination system that simultaneously excites a plurality of photosensitive markers dispersed in a two-dimensional array on the substrate, and an image acquisition and recording system having a field of view for light emission from the features on the substrate, the illumination A light source arranged to cover the two-dimensional array with light of an excitation wavelength along an illumination path arranged at an angle θ between about 20 ° and 50 ° relative to the plane of the substrate; The acquisition and recording system has an image acquisition axis substantially perpendicular to the plane of the substrate carrying the array, and includes a solid state array of photosensitive elements, such as a charge coupled device (CCD) or CMOS array. The image collection and recording system is configured and arranged to apply the feature array image to a solid state array of the same size as the array size, for example, about 25% enlarged or reduced to 75%. And the image acquisition and recording system has a moderate numerical aperture NA that allows recording of the fluorescent image from the excited two-dimensional array with clinical accuracy and without movement of the array.
Preferred embodiments of this aspect of the invention have one or more of the following technical features.
The array reading image acquisition and recording system has its closest component at a position spaced at least 5 mm, preferably at least 10 mm from the substrate or its support, which component illuminates a two-dimensional array on the substrate. Configure and arrange to provide space under the roadway components.
The image acquisition and recording system has an effective aperture between NA = 0.3 and NA = 0.60, and the value of NA is preferably between about 4.0 and 5.5.
Image acquisition recording system has a field of view on the substrate area between 50 mm 2 to 300 mm 2.
The lighting system comprises one or more light emitting diodes.
The illumination system and in particular the system utilizing diodes is constructed and arranged to provide excitation illumination for a two-dimensional array on a substrate with a power density exceeding 30 mW / cm 2 , preferably the image acquisition and recording system comprises a substrate Includes a timer cooperatively associated with the illumination system to provide sufficient exposure to produce an excitation radiation fluence of greater than about 15 mJ / cm 2 across the two-dimensional array.
The array reader has a field of view with a diameter of 10 mm or more.
Each feature of the array of interest is imaged on a solid state array of at least 50 pixel elements, eg, a CCD or CMOS element. (In the preferred case shown herein, the pixels of the solid-state array (ie, the detector elements) are chosen to be 9 microns in size, but when imaging a larger field of view, the same configuration is used, and about 4 Select a pixel down to .5 microns and use a larger reduction of the image).
The array reader is constructed and arranged to deliver an unenlarged field of view image to the solid state sensor, and preferably the reader produces a field of view image reduced between about 30% and 50%. Configured and arranged to feed to solid state sensor array.
The array reader is configured to image spots having a diameter of at least about 80 microns, preferably at least 100 microns in diameter.
The array reader is configured and arranged to generate an image of an array of at least 100 spots each having a diameter of 300 microns or at least 400 spots each having a diameter of 150 microns, during a single imaging period.
This array reader combines an array carrier comprising a substrate layer carried by the support body to make the image acquisition and recording system resident on the substrate on the same side as the feature array, and before the illumination path reaches the support body. The carrier absorbs the excitation radiation transmitted across the layer, preferably the support body is transparent, for example glass, and tends to enter the transparent body between the substrate layer and the transparent body. A substantially opaque adhesion layer that can substantially block the excitation radiation is resident, and the substantially opaque layer consists of a metal oxide layer.
The array reader is combined with an array carrier in the form of a transparent layer carried by the transparent body, and the image collection and recording system lies beyond the transparent body on the same array side as the transparent body.
The array reader is combined with an array carrier comprising an ultra-thin substrate layer on a support body, i.e. the substrate has a wall thickness of less than 5 microns, preferably less than about 3 microns.
The array reader is combined with a carrier having an array disposed on a substrate made of a transparent layer of nitrocellulose or polystyrene.
The array reader is combined with a carrier, wherein the substrate is a porous nitrocellulose membrane at least in its outer region.
The array reader is combined with a substrate carrying excitation energy reference features that are distributed throughout the two-dimensional array of features, and the image acquisition and recording system is located in the vicinity of the individual reference features based on the amount of radiation detected from the individual reference features. It includes a normalization configuration that normalizes the detected data.
The array reader has an illumination system with at least two different light source subsystems, each of a substantially different wavelength, each associated with a separate optical system that delivers light along the optical path, The optical paths of the system lie along different axes, the axes are spaced around the substrate, and in some preferred embodiments, two different light source subsystems with optical paths disposed at both ends of the substrate diameter. Exists.
The array reader is a light source selected to excite Cy3 and Cy5, respectively, and the image acquisition and recording system is a variable bandpass filter suitable to allow radiation paths from Cy3 and Cy5, respectively, or Cy3, Cy5 A lighting system with a single bandpass filter suitable to allow multiple bandpass radiation, such as both bandpass radiation.
The image acquisition and recording system of the array reader can be adjusted between at least two settings, the first and second settings being an array format with dimensions of 6.5 mm × 9.0 mm, and 4.5 × 13. They are individually constructed and arranged to form a single image in an array format with two individual small windows of dimensions 4.5 mm × 4.5 mm each arranged in a 5 mm rectangle.
The array reader illumination system includes a diode light source and a homogenizer effective to reduce flux density variations across the illumination field, and in some embodiments, the homogenizer is an elongated transparent internal reflective rod. Which is straight or curved, has a round or square or rectangular cross section and is twisted or untwisted.
The array reader has an image acquisition and recording system configured and arranged to resolve images on a solid state sensor array with a resolution of up to about 10 microns, and in some embodiments, the resolution is about 12-15 microns. Between.
The array reader has an image acquisition / recording system, which includes an interference filter, the light collection optical system of the system preceding the filter guides the collected light parallel to the filter, and the imaging optical system is a solid state sensor. The parallel light leaving the upper filter is imaged.
The array reader was configured for use with an array support holding one or more arrays, and the reader was configured and arranged to read and process each array as an independent array.
The invention also preferably comprises the preparation of a two-dimensional spotted array of amino acid or nucleic acid features on a substrate by spotting a liquid sample thereon, the features in the sequence carrying a fluorescent marker, The method of performing the analysis using any of the readers described above for reading the sequence.
This analysis is a diagnostic immunoassay based on a protein collected from blood, and in some embodiments preferably the immunoassay is an antibody capture configuration, eg, adapted with an immobilized antibody that detects or monitors malignant cancer. For example, initial diagnosis may detect ovarian cancer or monitor patients for risk of recurrence.
The substrate is placed in a sealed disposable biocassette, and imaging takes place through a transparent window that provides visual access to the substrate or a transparent body that forms the side of the biocassette, and the substrate is transparent The array is visually accessed by the array reader through the transparent body and through the substrate.
For any array reader embodiment for the described or any of the methods described above for reading an array on a substrate, in some preferred embodiments, the array is emission luminance relative to the excitation level over the entire operable illumination luminance range. And a system or method includes forming an image of the array using an array reader and normalizing the recorded array data based on quantitative data obtained from the near brightness calibration marker.
Another aspect of the present invention is a diagnostic method using a fluorescence reader for a disease in which a group of known protein biomarkers is present in blood or other human body components, and includes (1) two different reagents on a substrate. Providing a dimensional array and individually specializing the reagents to bundle the elements of a biomarker group capable of diagnosing the disease; and (2) an individual containing the biomarker when present in individual blood or human body components The step of exposing the array to the phosphor-labeled blood or human body component extract of (3), and (3) simultaneously illuminating the entire two-dimensional array with light of the fluorescence excitation wavelength using dark field illumination while the array is stationary (4) capturing a fluorescence image of the entire two-dimensional excitation array on a single frame of an imager comprising a solid state array; and (5) (e.g., The method comprising the steps of analyzing the fluorescence image for the presence of computer by) disease.
Preferred embodiments of this aspect of the invention have one or more of the following features.
In the method, the step of illuminating the entire two-dimensional array guides the excitation radiation from one diode or group of diodes and illuminates at a wavelength selected to excite the phosphor with a power density of at least 30 mW / cm 2. Perform what is done by generating.
The method is implemented in a manner that is distributed through the fluorescence intensity reference feature array and the detected radiation from the biomarker is normalized by a reader based on the response of the reference to the illumination.
The method is implemented in such a way that a solid state sensor of at least 50 pixels represents an image of the array features.
The method is performed with a biomarker attached to the antibody.
The method is performed in such a way that the sequence is configured to immobilize a protein biomarker selected to diagnose the presence of ovarian cancer.
Another feature of the present invention is a method for reading an array on a substrate having features including phosphors, the array having a fluorescence characteristic luminance that is generally proportional to the emission luminance for those illuminations over the entire operable illumination luminance range. Including calibration features, including image formation of the array using an array reader and normalization of recorded array data based on quantitative data acquired during reading of the array from neighboring luminance calibration features in the array.
The method is applied to perform a diagnosis for a disease in which a set of known protein biomarkers in blood or other human body components is present, (1) providing a two-dimensional array of different reagents on a substrate, An individualized step to bundle elements of a biomarker group capable of diagnosing a disease, the step of including a brightness calibration function in the array, and (2) a living body when it is present in the blood or human body component A step of exposing the array to the fluorescent substance-labeled blood or human body component extract of the individual including the marker; and (3) two-dimensional array using light of a fluorescence excitation wavelength using dark field illumination while the array is stationary. Exciting the array by simultaneously illuminating the whole; and (4) capturing a fluorescence image of the entire two-dimensional excitation array on a single frame of an imager comprising a solid state array. Including a flop, the step of normalizing the recorded sequence data based on the calibration characteristics of (5) in the array, and analyzing the fluorescence image for the presence of (6) diseases.
The method illuminates the entire two-dimensional array and produces illumination at a wavelength selected to guide excitation radiation from a diode or group of diodes to excite a phosphor with a power density of at least 30 mW / cm 2. This is done by forming an image.
The method is implemented with a solid state sensor of at least 50 pixels representing an image of the array features.
The method is used to perform a diagnosis where the sequence features include antibodies, and in one important case, the sequence features are selected to diagnose the presence of ovarian cancer.
Like reference symbols in the various drawings indicate like elements. Referring to FIG. 1, an array reading system 100 includes an array reader 110 and a two-dimensional array of features 103 (eg, biomaterial spots such as amino acids and nucleic acids), some of which carry fluorescent materials in response to analysis. And a computer 104 that processes an image recorded using the array reader 110. The array reader 110 includes an illumination system 120 and an image acquisition and recording system 140.
During operation, the substrate 102 is positioned below the image acquisition and recording system 140 using the positioner 105, but the distance h between them is sufficient for the light from the illumination system 120 to cover the two-dimensional array 103. To a large extent, preferably h has a value of at least 5 mm, generally preferably at least 10 mm. A suitable light source of illumination light has an output between about 30 mW / cm 2 and above, preferably a light emitting diode (LED) or an array of such diodes. Features on the substrate include materials that can emit in a narrow fluorescence spectrum upon excitation with light of a selected wavelength from the illumination system 120. Available fluorescent dyes can be used, where Cy3 and Cy5 are common choices.
The image acquisition and recording system 140 collects the fluorescence and records the generated image of the feature or spot, and the optical system has been selected to produce a flat field of view. The image acquisition axis 141 is substantially perpendicular to the plane of the substrate 102. The illumination system 120 uses dark field illumination to guide light from the illumination system 120 along an optical path having an angle θ between about 20 ° and 50 ° with respect to the plane of the substrate 102 and reflected by the substrate 102. Light is prevented from entering the image collection and recording system 140. The fluorescence emitted by the spot is a moderate numerical aperture, for example between NA = 0.30 and 0.60, in the preferred embodiment NA = 0.40, to increase the field of view and the amount of light collected. Light is collected by the imaging optical system 142 in the range between 0.55 (all in the air). The imaging optical system 142 projects an image 144 of the array 103 onto a two-dimensional array solid state detection element composed of sensors 146. This solid state array has dimensions of the same magnitude as the dimensions of the biological material spot array. The imaging optical system 142 is designed to have a large field of view that allows the entire array 103 to be mapped onto the sensor 146. In general, the two arrays are relative in size, and the biomarker spot is solved on at least 50 pixels, preferably in the 100-micron spot size of the 100-pixel range, or in the 300-micron spot size of the 300-pixel range. Image.
Using such a configuration, the physical dimension Di of the image 144 is approximately the same as the physical dimension Do of the array 103 biased towards reduction, ie, preferably enlarged beyond about 25%. And does not reduce beyond about 75%. Currently, the use of available components at a relatively low cost does not enlarge the arrangement and is preferably reduced within the range of 30% to 50%. This eliminates the need to transfer the array 103 with a precision stage for the reader 110 in order to acquire an image or stitch together a plurality of small portion images to form a single image of the array 103. An important feature is brought about.
Referring to FIG. 2A, in a preferred embodiment, the illumination system 120 emits light (eg, green) in an excitation band designed to excite the fluorescence spectrum of the material (eg, Cy3) in the spot. LED 122 is included. The excitation filter 124 is used to further limit the excitation wavelength band. The spatial distribution of light is shaped using an optical system such as a pair of lenses 126, 128, resulting in a substantially uniform illumination of the two-dimensional array 103 on the substrate 102. To provide brighter illumination, two or more LEDs arranged in an array 103 are also arranged to emit light along an optical path having an angle θ between about 20 ° and 50 ° with respect to the plane of the substrate 102. It can also be distributed around.
Referring to FIG. 2B, in another preferred embodiment, the illumination system 120 'includes a high intensity LED 132 that emits within an excitation band designed to excite the fluorescence spectrum of the material at the spot. The excitation filter 134 is used to further limit the excitation wavelength band. A homogenizer 130 with a suitable lens integrated at its end (not shown) reduces variations in the light flux density across the illumination field onto the two-dimensional array 103 located on the substrate 102. It is a solid transparent rod or cladding that is suitably designed to have 100% internal reflection, has a diameter versus length selected to provide the desired homogenization effect, and makes the illumination distribution function more uniformly. The homogenizer 130 receives light up to an acceptance angle of about 45 degrees. The end of the homogenizer 130 is configured to emit light along an optical path having an angle θ between about 20 ° and 50 ° with respect to the plane of the substrate 102.
There are improvements that can be carefully combined with the reader to improve the performance of the reader and make it practical in a variety of important contexts.
At least one, preferably using a distribution of energy calibration spots within each array, the detected brightness for the spots of the array is normalized to the radiation detection values received from the calibration spots lying down during image processing, thus lower cost illumination Non-uniformity tolerances in the radiation that can occur in the system can be allowed. The technique can also be effective in compensating for inaccurate position of the lower array of the reader. FIG. 3 shows a non-uniform illumination pattern generated by a typical high-brightness LED plotting the relative brightness as a function of angle from the central axis. The fluorescence brightness recorded by the solid-state sensor array at a predetermined position in the image corresponding to the calibration spot is used to estimate the local illumination brightness, and this brightness is normalized to the signal level recorded at the adjacent spot on the sensor array. Used to convert In general, different calibration spots, each local, are used for different sets of spots of unknown brightness.
The calibration points are preferably placed on the substrate together with an array of biological spots for precise relative placement. FIG. 4A shows a well of a microwell plate containing a fluorescence calibration composition that accepts a composition that immerses pins 161 to spot a substrate 102, for example, a polyimide polymer (Kapton ™) dissolved in a volatile solvent. Represent. FIG. 4B schematically illustrates a spotted array 103 of biological spots 166 with a pattern of fluorescent calibration spots 164 in between that produces the composition of FIG. 4A. FIG. 4C is an enlarged view of a portion of the substrate 102 that includes the fluorescence intensity calibration spot 164 in addition to the biological spot 166. FIG. 4D is a schematic plan view of the array 103 of biological spots 166 showing the relative arrangement of the calibration spots 164 in an enlarged size. This device allows normalization of luminance variations over the entire array 103. The same brightness calibration spot can be used as a spatial reference to place the array, or it can be used to place it into the control system using the overall geometry of the arrangement.
By utilizing large sized spots, i.e. those reasonably sized images on a solid state array, there is no enlargement, but another improvement is a solid state array image that helps average out random noise. This is the binning of the pixels inside. The on-board binning capability of the conventional CCD supplied in this way is used to increase the reading accuracy. FIG. 5 shows a portion of the CCD near the image boundary of the spot 202 corresponding to allowing resolution of features in an array of approximately 291 pixels.
Other significant improvements require the provision of special features and characteristics of the substrate and its support that reduce automatic fluorescence capture (ie, fluorescence collected from a light source other than the fluorescent material within the array features). . FIG. 6 illustrates an important aspect of a preferred substrate 102. The ultrathin layer 302 of material (eg, less than about 5 microns, preferably less than 3 microns) is made of, for example, nitrocellulose or polystyrene. As a film it is transparent, although in other cases an ultra-thin porous nitrocellulose membrane can be used. A substrate supports the feature array 103. Since its presence is extremely thin, it limits the amount of fluorescence emitted by the substrate layer 302 itself.
The opaque layer 304, such as sputtered metal oxide, prevents the illumination light 300 from penetrating into the interior and stimulates fluorescence within the rigid support 306 on the lower side (eg, a substrate comprising a glass microscope slide). Useful. This helps counter the potential automatic fluorescence capture from the support layer 306 caused by the large depth of focus due to not using large numerical aperture optics.
The array reader 110 captures sequences of fluorescently labeled proteins as well as other potential broad applications such as imaging labeled proteins with fluorescent tags or other biomaterials with fluorescent or luminescent tags. Is also possible. The array reader 110 can be used with viruses, peptides, antibodies, receptors and other proteins, with a wide range of other labeled biomaterials including plants, animals, humans, fungi and bacterial cells, and with labeled chemicals. It can be used effectively. The array reader 110 is generally designed for rapid imaging of immunoassay arrays of less than 1000 spots and sized for clinicians.
The array reader 110 can also simultaneously perform immunoassays of a plurality of biomarkers (eg, ovarian cancer). Using known protein biomarkers in blood or other human body components, the disease can thus be diagnosed more easily. After supplying the two-dimensional spot arrangement reagent on the substrate, the reagent spot is exposed to blood labeled with a fluorescent substance or other human body components collected from an individual suspected of having a disease. The resulting spot array is then read by the array reader 110.
Referring to FIG. 7A, in the preferred embodiment here, a light source originally designed for traffic lights is used, and two light emitting subsystems are arranged at both diameter ends around the array location. The array reader 400 is a LumiLed high-intensity LED 402 with a green peak wavelength for Cy3 excitation (Luxeon green 535 nm available from Lumileds Lighting US, LLC, San Jose, Calif.). 5 Watt LEDs, part number # LXHL-LM5C) and second Lumired high brightness LED 404 (Luxeon red-orange 617 nm, 1 Watt LED, part number # LXH-MH1B) with a peak wavelength for Cy5 excitation. Both LEDs have a low temperature coefficient of approximately 0.04 nm / ° C. and a narrow band peak wavelength tolerance of 8 nm for Cy5 and 30 nm for Cy3. These LEDs have a conversion efficiency of 10% to 20% and a 50% peak for the second with a low duty cycle and are available with a normal 110mW continuous wave that can yield about 150mW Almost all are in the passband of the Cy3 excitation filter 406 (chroma filter part number # HQ535 / 50 available from Chroma Technologies, Rockingham, Vermont) and the Cy5 excitation filter 408 (chroma filter). Product number # HQ620 / 60). The f / 1 cone (represented by the 30 ° line 150 in the illumination pattern shown in FIG. 3) contains 21.5% light, ie 64.5 mW (the larger capture is the acceptance of the homogenizer of FIG. 2B). It is possible with an angle of 45 degrees). However, all light within the f / 1 cone does not transfer through the f / 1 lens due to Fresnel reflection at higher angles. By using appropriate filtering and vignetting, it is safe to expect 50 mW (almost 33% transfer efficiency) in a 10 mm diameter round beam 10 for the red LED 404 that does not have a spatial brightness of 20%. By tilting the beam by 45 °, the light is diffused throughout the ellipse surrounding the desired 6.5 × 9.5 mm 2 area, resulting in a power density of about 45 mW / cm 2 . In 0.5 seconds it gives a fluence of 22.5 mJ / cm 2 . In comparison, the excitation energy of a laser confocal microscope is approximately 5 mW per 10 micron diameter over approximately 7.5 microseconds, resulting in a fluence of 48 mJ / cm 2 . Similar performance is obtained for green LED 402 with peak absorption for Cy3. In addition to high power and cost efficiency, LEDs have a long life, allowing simple mounting of multicolor phosphors. The green LED 402 uses a pair of Koehler lenses 412 and the red-orange LED 404 uses a pair of Koehler lenses 414 so that both LEDs deliver a nearly uniform beam over a field of view of 6.5 × 9.5 mm 2 in the array 103. To do. LEDs are mounted on heat sinks available from their suppliers.
The positioning of the substrate 102 with respect to the field axis of the reader is done by a positioner 105, for example, a Geneva gear with a spatial resolution of 0.1 or 0.2 mm with a positioning accuracy of about 0.1-0.2 mm. The The positioner 105 can be used to automatically transition from one array image to another array image on either the same or different substrates, but of course not the accuracy or cost of the microscope stage, but the array image. It does not play any role in the generation of components. The same substrate can carry many arrays without having to accurately position the arrays with respect to each other, and the positioner 105 functions to move from position to position to the position for imaging. Preferably, the substrate has an "origin" that serves to position alignment marks, ie, prominent marks that specify, for example, corners of a rectangular array.
Array 103 includes a pair of commercial CCD lens assemblies 422, 422 '(Westtech CCD lens assembly part numbers # 2105 and # 2131 available from Westech Optical Corporation of Penfield, NY. ), The lens 422 is used in a unique way for its original design purpose. A band-pass filter 424 (Cy5 chroma technology component # 68030, Cy3 chroma component # 57030) positioned between the two lenses selectively transmits only light within the excitation fluorescence spectrum. An image with a field of view of 6.5 × 9.5 mm 2 (see 502 in FIG. 8) is projected onto the CCD sensor 420 reduced to 0.707 times, but within a rectangle of 4.50 × 13.5 mm. Two lying sub-array images are scaled down by a factor of 0.5.
The lens is assembled to operate with 0.42 NA on the subject side (opposite the array 103). The array 103 can be imaged on a CCD sensor 420 with a lens assembly 422 assembled to operate with an NA as large as 0.52.
CCD sensor 420 uses a Peltier cooler 426 (camera model number ST-7xME using a CCD from Santa Barbara Instrument Group, Inc., Santa Barbara, Calif.) To reduce dark current noise. Cool down. The cooler 426 has an ability to cool the CCD sensor 420 to 50 ° C. lower than the environment as needed. Despite favorable cooling, the read noise generated when converting the charge accumulated in the pixel to voltage is the dominant noise source, and unless the effect is ruled out, the read noise is the lowest that can be detected. Determine the light intensity. Since this noise is random and not the fluorescence from the spot, most of its effects are "on-board binning", darkfield subtraction, time and frame integration, software analysis, and the large number of pixels that image each spot. It can be reduced by use.
Referring to FIG. 7B, imaging in the dark field mode is performed along the axis A perpendicular to the array plane via direct illumination at the illustrated angle θ and a condensing optical system 27 spaced a distance h from the substrate. It can also be achieved by using a CCD sensor 24 arranged to visually recognize the arrangement. In this case, the substrate layer may be microporous, partly or throughout its depth, or it may be a solid film or a modified solid film, preferably in either case less than 5 microns thick It can be a very thin coating or a thin film. As shown in the drawing, direct illumination light is incident on the arrangement plane at an acute angle θ along the illumination axis A ′. With the angle θ illustrated in the range of about 20 ° to 50 °, here 45 °, the distance h must be selected to allow this kind of illumination. The light L from the light sources 112a, 112b, or 112c of the wavelength selected to excite the phosphor tags in the array is located on the side that directs illumination along the axis A ′ at an angle θ through the dichroic mirrors 156b, 156c. To the mirror 116 that goes on the phosphor-tagged spot array on the ultrathin substrate 20 or 20 '. For the arrangement of the spots, a carrier having an ultra-thin substrate layer on the support body or a carrier in the form of a transparent layer carried by the transparent body can be used. Lying over the transparent body. The fluorescent emission is collected by the lens 27 via the selected filter 28A, 28B, or 28C, where it enters the CCD camera 24 via the lens 26 under the control of the computer 32. As before, the background subtraction technique is used with the system. The difference between the excitation source and that of FIG. 7A leads to significant costs that go counter to the most cost-effective situation of clinical practice, but the advantage of the different capabilities of the illumination system structure of FIG. 7B to enjoy other described benefits. Can have.
In an advantageous design, the immunoassay array is limited to 400 fine analysis spots. The array format is an important design issue there. The size and number of pixels of the CCD chip and the configuration of the commercial spotting array are important constraints that must be matched in the reader and array design. The array dimensions must be matched to the CCD parameters. On the other hand, spot forming pins and chip configurations limit the choice of reservoir for loading spot forming or print heads to the source material, and also limit possible arrangements. 96 or 384 disposable microtiter plates are common reservoirs to use. These constraints are satisfied by the two forms shown schematically in FIG.
By taking into account geometrical tolerances, the first type 502 field of view covers one 6.5 × 9.5 mm 2 array and the second type 504 field of view is two 4.5 × 4.5 mm 2. Covers the array. Assuming a 300 micron diameter spot, 500 microns in the middle, and a spot occupancy of 36%, each spot will be joined to about 291 pixels. Assuming a 150 micron diameter spot, 333 microns in the middle, each spot would be joined to about 91 pixels. The large number of pixels per spot provides an on-board 3x3 binning option available to the CCD sensor and increases the signal to noise ratio. The intermediate background is subjected to the same averaging, resulting in a sensitive and reliable fluorescence signal level. The array can be formed with each type using either of two spot dimensions. These arrays start with either 96 or 384 microtiter plates as source material loading reservoirs, and include any commercial arrayer / printer such as the Affymetrix Pin or Ring Arrayer. Can be used for printing.
Other methods help to improve the signal-to-noise ratio and best define the image quality. Longer integration times, i.e. multiple acquisition sums of static arrays, help to avoid CCD saturation. The signal to noise ratio is improved as the square root of the integration time ratio or the number of frames. A read time of 0.5 seconds to 5 seconds improves the signal to noise ratio by approximately 3.16 times.
The signal to noise ratio can also be increased by increasing the number of LEDs to, for example, about 4 for each of the two wavelengths and increasing the power level to 160 mW / cm 2 . When applied together, these options increase the signal-to-noise ratio by as much as 13 times by increasing the fluence to about 1,120 mJ / cm 2 . Photobleaching, i.e. possible outcomes, may limit this approach in certain environments depending on the dye and the like.
Alternative embodiments can use other types of substrates. For example, the substrate can be a glass slide or a sealed disposable biocassette that images through a transparent window in the substrate.
Referring to FIG. 9, the multiple biomarker analysis method includes a step 600 of disposing a two-dimensional spotted array of amino acid or nucleic acid features on a substrate, wherein the features of the entire array carry a photosensitive marker. . In a second step 602, the illumination light source of the array reader illuminates the array along the illumination path at an angle θ between approximately 20 ° and 50 ° with respect to the substrate plane. In a third step 603, the image acquisition and recording system then collects the excitation fluorescence along an image acquisition axis that is substantially perpendicular to the substrate, which is imaged of an image of an array of biomaterial spots on a solid array of CCD sensors. A recording step 604 follows, followed by a step 606 of normalizing the luminance level of the pixels in the recorded image using a luminance calibration marker.
Note that this calibration occurs as an integrated function in each array imaging. The pre-read calibration of the entire instrument should be identified as a normal but not totally effective procedure.
Referring to FIG. 10, a method for normalizing the luminance level of pixels in a recorded image includes determining 1004 pixels that detect fluorescence from position calibration spots located at the corners of array 1002. . The obtained position information is used to arrange pixels corresponding to a plurality of "data groups" in the entire two-dimensional image. Each data group includes a pixel corresponding to the biological spot, and the pixel corresponds to a luminance calibration spot. For each data group that includes "data group n", the method detects the luminance recorded by the pixel representing luminance calibration spot n 1006 and recorded by the pixel representing each biological spot in data set n. Step 1008 for detecting the luminance and Step 1010 for normalizing the luminance data for each biological spot using the luminance of the luminance calibration spot. After normalizing the luminance data for each data group in the final step 1012, the entire image is represented according to the normalized data for the entire data set.
Referring to FIG. 11, a diagnostic method using a fluorescence reader for a disease in which known protein biomarkers in blood or other human body components are present has a two-dimensional array of different reagents on a substrate. Step 1102 is included. Each reagent is unique to bundling a member composed of a set of biomarkers capable of diagnosing a disease. The method then includes a second step 1104 of exposing the array to an individual's phosphor-labeled blood or human body extract containing biomarkers if present in the individual's blood or human body component. While the array is stationary, in a third step 1106, the reader excites the array by simultaneously illuminating the entire two-dimensional array with light of the phosphor excitation wavelength and uses dark field illumination. In a fourth step 1108, the reader then captures a fluorescence image of the entire two-dimensional excitation array on a single frame of the imager consisting of a solid state array. The method then includes step 1110, which consists of analyzing a fluorescent image for the presence of a disease.
In a preferred embodiment, the analysis is a diagnostic immunoassay based on a protein taken from the blood, detecting or monitoring a malignant cancer such as ovarian cancer, or initially monitoring or monitoring a patient at risk of recurrence. it can. In recent decades, searching for biomarkers alone or in combination with Ca125 can improve prognostic testing for ovarian cancer producing a large number of candidates. However, in 1995, Belek and Bast reviewed the data on 17 different markers (including CA125) and concluded that none were effective in the early stage ovarian cancer setting (1 ). However, it has been shown that other tumor markers can complement CA125 and are useful in some circumstances (2).
In recent years, genomic technology has dramatically accelerated progress in the search for prognostic ovarian cancer biomarkers. Studies using differential DNA transcription profiling of ovarian cancer cell lines and studies from ovarian epithelium have collectively identified hundreds of candidate biomarkers (eg, 3, 4, 5). These novel candidate protein biomarkers have been evaluated in research trials. Candidate biomarker proteins studied include HE4 (6) and osteopontin (7), prostasin (4,5), mesothelin / meganuclear cell enhancement factor (8) . Recent reports also suggest that elements of the kallikrein serine protease system, particularly kallikrein 10, may also serve as a biomarker for ovarian cancer in blood (9, 10, 11). Results from research studies have encouraged and suggested that these proteins can serve as prognostic indicators for ovarian cancer, either alone or in combination with other markers such as CA125.
There is direct evidence that patterns of multiple biomarkers in the blood provide early stage ovarian cancer signals. The protein spectrum generated from the sera of ovarian cancer patients and healthy individuals by mass spectroscopy (SELDI-TOF) and analyzed by an iterative search algorithm identifies five protein profiles that have not yet been identified. Of sera were fully identified (12). Blindfold sample testing accurately identified 100% of ovarian cancer samples with a special pattern of 36% from patients at an early stage and showed a 95% characteristic (false positive rate) (12).
If the positive predictive value of protein pattern technology is supported in population-based trials, these discriminating proteins offer an excellent opportunity to develop sensitive diagnostic probes (13), which are When given an appropriate technology platform, it will eventually be used in routine trials aimed at detecting early stage ovarian cancer.
The cited references are as follows.
1. Berek, JS, RC Bast, 1995, "Screening for ovarian cancer, use of continuous complementary tumor markers with improved sensitivity and properties for early detection", Cancer 76 2092-060000
2. Woolas, RP, DH Oran, AR Jayarajah, RC Bus, JJ Jacobs, 1999, "Ovarian cancer identified through screening using serum markers rather than pelvic imaging", 1999. Int. J. et al. Gynecol 9: 497-501
3. Schummer, M, WV Ng, RE Bummarner, PS Nelson, B Schummer, DW Bednarski, L Hassell, BY Baldwin, L. Hood, 1999, "Comparative Hybridization of Sequences of 21,500 Ovarian cDNAs for Discovery of Overexpressed Genes in Ovarian Cancer", Gene238: 375-385
4). Kwong-Kwok, W, RS Cheng, SC Mok, 2001, "Identification of differentially expressed genes from ovarian cancer cells by MICROMAX ™ cDNA microarray system", 2001. Biotechniques 30 (3): 670-674
5. Mok, S, J Chao, S Skates, K-K Wong, GK Yu, MG Muto, RS Berkowitz, DW Cramer, 2001, "Prostasin, a potential serum marker for ovarian cancer: identification via microarray technology" , JNCI 93 (19): 1458-1464.
6). Hellstrom, I, J .; Raycaft, M Hayden-Ledbetter, JA Ledbetter, M Schummer, M McIntosh, C.I. Drescher, N Urban, KE Hellstrom, 2003, "HE4 (WFDC2) protein is a biomarker for ovarian cancer", Cancer Research 63; 3695-3700.
7). Kim, JH, SJ Skates, T Ude, KK Wong, JO Schorge, CM Feltmate, RS Berkowitz, DW Cramer, SC Mok, 2002, "Osteopontin as a potential biomarker for ovarian cancer", JAMA 287 (13 ): 1671-9
8). Scholler N, N Fu, Y Yang, Z Ye, GE Goodman, KE Hellstrom, I Hellstrom, 1999, "One or more soluble materials of mesothelin / meganuclear cell enhancing factor detected in serum from ovarian cancer patients Is possible ", PNAS USA 96 (20): 11531-6 (discovered in L. Hood screening study).
9. Shvartsman, HS, KH Lu, J Lillie, MT Devavers, S Clifford, JI Wolf, GB Mills, RC Bast, DM Gershson, R Schmundt, 2003, "Kallikrein G of epithelial ovarian carcinoma 90c" -50
10. Luo, LY, D Katsaros, A Soriras, S Fracchiolo, R.M. Riccinno, IA Rigault de la Longris, DJC Howart, EP Diamandis, 2001, "Prognostic value of human kallikrein 10 expression in epithelial ovarian cancer", Clin Can Res7: 2317-2379.
11. Luo, LY, D Katsaros, A Scoralas, S Fracchioli, R Bellino, M van Gramberen, H de Bruijn, A.M. Henrik, UH Stemanman, M Massobrio, AG van der Zee, I Vergote, EP Diamandis, 2003, "Serum Prognosis", Cancer Res 63: 807-11
12 Petricoin, EF, AM Ardekani, BA Hitt, PJ Levine, VA Fusaro, MA Steinberg, GB Mills, C Simone, DA Fishman, EC Kohn, LA Liotta. Lancet 16: 359 (9306); 572-77.
13. Wulfkuhle, JD, LA Liotta, EF Petricoin, 2003, "Proteomic application for early detection of cancer", Nature Reviews Cancer 3: 267-75.
Subject (1) Use of properties of ultra-thin substrate layers in dark field illumination, in general, solid state arrays of magnitude sensors, in particular nitrocellulose and polystyrene, and their manufacturing methods and applications in the order of the size of spot arrays Imaging above, (2) metal oxides and other absorbing layers under the substrate that absorb excitation light to help improve operation and make clinical fluorescence readers practical, and (3) especially high brightness For further disclosure regarding the formation and utilization of luminance calibration marks in a microarray that helps to improve the operation of a fluorescence reader in light emitting diodes or those using a diode array that excites illumination, see the application filed June 6, 2003. See further PCT application filed concurrently with the present application claiming priority from US Provisional Patent Application No. 60 / 476,512.
Other features and advantages of the invention will be understood from the foregoing and claims, but are within the spirit and scope of the invention.
1 is a diagram of an array reading system. It is the schematic of the illuminating device for readers. It is the schematic of the illuminating device for readers. It is a figure which shows the plot of the relative luminance of the illumination with respect to the angle made with respect to the central axis for high-intensity LED. FIG. 4A is a diagram showing spot forming pins and reservoirs suitable for forming biomaterial spots, that is, luminance calibration spots. FIG. 4B shows an array of calibration spots that are strategically distributed through an array of biomaterial spots. FIG. 4C is an enlarged view of FIG. 4B. FIG. 4D is a plan view of FIG. 4B. It is a figure which shows the mapping of the spot on the solid-state detection element arrangement | sequence of a sensor. Illustrated on a high magnification scale is a carrier comprising an opaque layer, an ultrathin substrate, and a transparent rigid support body carrying an array spot on the substrate, with illumination from the same side as the array. FIG. 7A is a diagram representing a preferred clinical sequence reader. FIG. 7B shows another clinical sequence reader. It is a figure which shows the two arrangement | sequence standards which can be imaged with the arrangement | sequence reader of FIG. 7A. It is a diagram showing the steps of the array reading method. FIG. 6 is a diagram representing the steps of a method for normalizing the luminance level of a pixel of a recorded image. FIG. 6 is a diagram illustrating steps of a diagnostic method using a fluorescence reader.
In an array reader (110), suitable for clinical purposes to read a two-dimensional array (103) of features on a flat substrate (302), said features carrying a photosensitive marker, which can emit light upon excitation. There,
An illumination system (120) for simultaneously exciting a plurality of photosensitive markers distributed in a two-dimensional array on the substrate;
An image acquisition and recording system (140) having a field of view for light emission from the feature on the substrate;
The illumination system (120) is two-dimensionally arrayed with light of an excitation wavelength along an illumination path (P) disposed at an angle (θ) between about 20 ° and 50 ° with respect to the plane of the substrate. A light source arranged to cover (103);
The image acquisition and recording system (140) has an image acquisition axis (141) substantially perpendicular to the plane of the substrate (102) carrying the array, and a solid state array of photosensitive elements (203 in FIG. 4). For example, a charge-coupled device (CCD) or CMOS array is used, and the image acquisition and recording system has the same size as the array size Do, for example, an enlargement of about 25% or a reduction of 75%. (Dc) has a two-dimensional sensor (146) constructed and arranged to apply an image of a feature array to the solid state array, the image acquisition and recording system (140) having clinical accuracy and An array reader having a medium numerical aperture NA that allows recording of the fluorescent image from the excited two-dimensional array without the array transition.
The image acquisition and recording system (140) has its closest component spaced at least 5mm, preferably at least 10mm (dimension h) from the substrate (102) or its support, the component being on the substrate The array reader according to claim 1, wherein the array reader is constructed and arranged to provide space under the part for the illumination path (P) to the two-dimensional array.
The image acquisition and recording system has an effective aperture between NA = 0.3 and NA = 0.60, and a suitable NA value is between about 4.0 and 5.5. Or the array reader according to 2.
The image acquisition recording system (140) has a field of view (V in FIG. 1 and FIG. 7B) on the substrate region between about 50 mm 2 to 300 mm 2, according to any one of claims 1 to 3 Array reader.
The array reader according to any one of the preceding claims, wherein the illumination system comprises one or more light emitting diodes (122).
6. The illumination system of claim 5, wherein the illumination system is configured and arranged to provide excitation illumination on a two-dimensional array (103) on a substrate (102) having a current density greater than 30 mW / cm < 2 >.
The image acquisition and recording system (140) is cooperatively associated with the illumination system and is sufficient to generate a constant fluence of excitation radiation on the substrate above about 15 mJ / cm 2 across the two-dimensional array. 8. An array reader according to claim 6 or 7, comprising a timer for effecting exposure.
The array reader according to claim 1, wherein the field of view (V) of the array reader has a diameter (Do) of 10 mm or more.
The spot (166, 202) of the feature array is imaged on at least 50 pixel elements, for example a CCD or CMOS element, of the solid state array (203). Array reader.
10. The array reader according to any one of claims 1 to 9, wherein the array reader is configured and arranged to feed a non-enlarged field image to the solid state sensor array (203).
11. Array read according to any one of the preceding claims, wherein the solid state sensor array (203) is arranged and arranged to feed a field image reduced between about 30% and 50%. vessel.
12. Any one of claims 1 to 11 configured and arranged to image a two-dimensional array (103) of at least 100 spots (202) each having a diameter of at least about 80 microns, preferably at least about 100 microns in diameter. 2. The array reader according to item 1.
13. Any one of claims 1 to 12, configured and arranged to generate an image of an array of at least 100 spots of each 300 micron diameter or at least 400 spots of each 150 micron diameter during a single imaging interval. The array reader according to item.
In combination with an array carrier (102) comprising a substrate layer (302) carried by a support body (306), the image acquisition and recording system (140) is resident on the substrate on the same side as the feature array, and the illumination 14. The path of (P) of the first phase (P) before reaching the support body (306), so that the arrangement (103) is reached, and the carrier absorbs excitation radiation transmitted through the layer. The array reader according to any one of the preceding claims.
The support body (306) is transparent, for example, glass, and substantially blocks excitation radiation that tends to enter the transparent body between the substrate layer (302) and the transparent body (306). 15. An array reader as claimed in claim 14 in which a substantially opaque adherent layer (304) is resident.
The array reader of claim 15, wherein the substantially opaque layer comprises a metal oxide layer.
The substrate (302) is in the form of a transparent layer carried by a transparent body (306), and the image collection and recording system (140) lies across the transparent body on the same side of the array as the transparent body. The array reader according to claim 1.
In combination with a carrier (102) for the array (103) comprising an ultra-thin substrate layer (302) on the support body, ie a substrate having a thickness of less than about 5 microns, preferably less than about 3 microns. 18. The array reader according to any one of items 17 to 17.
19. An array reader according to any one of the preceding claims, wherein the array (103) is arranged on a substrate (302) comprising a transparent layer of nitrocellulose or polystyrene.
19. The array reader according to any one of claims 1 to 18, wherein the substrate (302) is a porous nitrocellulose membrane at least up to its outer region.
In combination with a substrate (302) carrying excitation energy reference features (166) distributed throughout the features of the two-dimensional array, the image acquisition and recording system (140) is individually based on the amount of detected radiation from the individual reference features. 21. The array reader according to claim 1, comprising a normalization configuration (see FIG. 10) for normalizing data detected in the vicinity of the reference feature.
The illumination system (120) is at least two different light source subsystems (402, 412, 406, 404, 414, 408 in FIG. 7A), each of substantially different wavelengths, each delivering light along an optical path. 22. The subsystem according to any one of the preceding claims, comprising the subsystem associated with an individual optical system, wherein the subsystem optical paths to the substrate lie along different axes, the axes being spaced about the substrate. 2. The array reader according to item 1.
23. An array reader according to claim 22, comprising two different light source subsystems, the signal paths of which are arranged at both ends of the diameter around the substrate (FIG. 7A).
The illumination system comprises light sources (eg, diodes 402, 404) selected to excite Cy3 and Cy5, respectively, and the image acquisition and recording system (140) allows radiation paths from Cy3 and Cy5, respectively. A single bandpass filter (424 suitable for allowing multiple bandpass radiation, such as a variable bandpass filter (424, 424 'in FIG. 7A) suitable for, or both Cy3 and Cy5 bandpass radiation 24. The array reader according to any one of claims 1 to 23, comprising:
The image acquisition and recording system (140) is adjustable between at least two settings, the first and second settings being an array format with dimensions of 6.5 mm × 9.0 mm (504 in FIG. 8); Or so as to form a single image in the form of an array, arranged in a 4.5 × 13.5 mm rectangle (502 in FIG. 8) with two individual small windows each measuring 4.5 mm × 4.5 mm. 25. An array reader according to any one of claims 1 to 24 arranged and arranged individually.
26. The lighting system of any of the preceding claims, comprising a diode light source (132) and a homogenizer (130 in FIG. 2B) effective to reduce variations in light flux density across the illumination field. 2. The array reader according to item 1.
27. The homogenizer (130) comprises an elongated transparent internal reflective rod, which is straight or curved, has a round, square or rectangular cross-section and is twisted or untwisted. The described array reader.
28. The image acquisition and recording system (140) constructed and arranged to resolve the image on the solid state array (203 in FIG. 4) with a resolution of up to about 10 microns. 2. The array reader according to item 1.
29. The array reader of claim 28, wherein the resolution is between about 12 and 15 microns.
The image collection and recording system (140) includes an interference filter (424 in FIG. 7A), and the condensing optical system (422) of the system in front of the filter guides the condensed light in parallel with the front filter. 30. The array reader according to any one of claims 1 to 29, wherein the imaging optical system (422 ') is configured to image parallel light leaving the filter on the solid state sensor (420). .
31. A reader as claimed in any one of the preceding claims, used in conjunction with an array support holding two or more arrays, wherein the reader is configured and arranged to read and process each array as an independent array.
Preparing a feature of an amino acid or nucleic acid that is two-dimensionally spot-aligned on a substrate, preferably spotting a liquid sample thereon, wherein the feature of the entire array carries a photoreactive marker; and 32. A method of performing an analysis comprising: using a reader according to any one of claims 1-31 to read.
33. The method of claim 32, wherein the analysis is a diagnostic immunoassay based on blood derived proteins.
33. The method of claim 32, wherein the immunoassay consists of an antibody capture configuration using an immobilized antibody.
35. The method of claim 34, provided to detect or monitor malignant cancer.
36. The method of claim 35, applied to the detection of ovarian cancer in an initial diagnosis or monitoring of a patient's risk of recurrence.
The substrate is disposed in a sealed disposable biological cassette (4 in FIG. 7B), and imaging is performed through a transparent window that provides visual access to the substrate, or a transparent body is the biological cassette. And the substrate is transparent, such as an ultrathin nitrocellulose or polystyrene layer, and the array is viewed through the transparent body and the array reader through the substrate. 37. A method according to any one of claims 32 to 36, wherein access is made automatically.
The array reads an array on the substrate that includes a luminance calibration feature (164) of fluorescence characteristics that is approximately proportional to the overall brightness of the illumination that can be manipulated, and using an array reader. 32. An array reader according to any one of claims 1 to 31, comprising normalizing the recorded array data (eg, spot 166 in FIG. 4C) based on the amount of data obtained from the formation and near luminance calibration features. Or a method according to any one of claims 32 to 37.
A diagnostic method using a fluorescence reader for a disease in which a set of known protein biomarkers in blood or other human body components exists, and (1) a two-dimensional array (103) of different reagents on a substrate And a step of individually specializing the reagent to bundle elements of the biomarker group capable of diagnosing the disease, and (2) an individual including a biomarker when present in the blood or human body component of the individual Exposing the array to phosphor-labeled blood or a human body component extract, and (3) leaving the array stationary and using dark field illumination with light of a fluorescence excitation wavelength (eg, FIG. 120) exciting the array by simultaneously illuminating the entire two-dimensional array; and (4) the two-dimensional excitation array on a single frame of an imager comprising a solid-state array. The entire fluorescence image (e.g., 140 by the FIG. 1) includes the steps of capturing, and analyzing the fluorescence image for the presence of (5) (for example, by the computer 104 of FIG. 1) disease.
The simultaneous illumination step of the entire two-dimensional array was chosen to guide the excitation radiation from the diode (122, 132, 402, 404) or group of diodes and excite the phosphor with a power density of at least 30 mW / cm 2 . 40. The method of claim 39, wherein the method is performed by generating a wavelength illumination.
41. The fluorescence intensity reference feature (164) is distributed through the array and detected radiation from the biomarker is normalized by the reader based on the reference response to the illumination. The method described.
42. A method according to any one of claims 32 to 41, wherein a solid state sensor of at least 50 pixels represents an image of the array feature.
43. A method according to any one of claims 39 to 42, wherein the biomarker is attached to an antibody.
44. A method according to any one of claims 39 to 43, wherein the sequence is formed to immobilize a protein biomarker selected to diagnose the presence of ovarian cancer.
A method of reading an array on a substrate having features including phosphors, comprising:
The array includes a brightness calibration feature of fluorescence characteristics that is generally proportional to the emission brightness for those illuminations over the entire operable illumination brightness, forming an image of the array using an array reader, and neighborhood brightness calibration within the array Normalization of the recorded sequence data during the reading of the sequence from the features;
Including a method.
Applied to perform a diagnosis for a disease in which a known protein biomarker set in blood or other human body components is present, (1) a two-dimensional array of different reagents on a substrate, and the reagent is placed in the disease A step of individually specializing to bundle elements of the biomarker group capable of diagnosing, and including the step of including the brightness calibration function in the array; and (2) when present in an individual's blood or a human body component Exposing the array to an individual phosphor-labeled blood or human body component excised body containing a biomarker in (3), and (3) light having a fluorescence excitation wavelength using dark field illumination while the array remains stationary Exciting the array by simultaneously illuminating the entire two-dimensional array by: (4) the entire two-dimensional excitation array on a single frame of an imager comprising a solid state array Capturing a fluorescent image; (5) normalizing the recorded sequence data based on the calibration features in the sequence; and (6) analyzing the fluorescent image for the presence of disease. 46. The method of claim 45.
Illuminating the entire two-dimensional array and generating illumination at a wavelength selected to excite the phosphor with a power density of at least 30 mW / cm 2 by guiding excitation radiation from one diode or group of diodes. 47. A method according to claim 45 or 46, wherein the image is formed.
49. A method according to any one of claims 32 to 48, wherein the sequence features are used to perform a diagnosis involving antibodies.
50. The method of claim 49, wherein the sequence features are selected to diagnose the presence of ovarian cancer.
JP2005502064A 2002-08-16 2003-08-18 Fluorescence sequence reading Pending JP2006515065A (en)
PCT/US2003/025702 WO2004017374A2 (en) 2002-08-16 2003-08-18 Reading of fluorescent arrays
JP2005502064A Pending JP2006515065A (en) 2002-08-16 2003-08-18 Fluorescence sequence reading
JP2005501757A Expired - Fee Related JP4678516B2 (en) 2002-08-16 2003-08-18 Substrates for material separation, reaction, and microscopic analysis
AU (2) AU2003269968A1 (en)
JP2009522578A (en) * 2006-01-04 2009-06-11 フジレビオ アメリカ、インク. Use of HE4 and other biochemical markers to determine ovarian cancer
JP2009229398A (en) * 2008-03-25 2009-10-08 Toyo Kohan Co Ltd Detecting method of fluorescent labeled molecule related with living body
JP2015057600A (en) * 2008-05-20 2015-03-26 ユニバーシティー ヘルス ネットワーク Device and method for fluorescence-based imaging and monitoring
US9523682B2 (en) 2011-11-16 2016-12-20 Becton, Dickinson And Company Methods and systems for detecting an analyte in a sample
US9678065B2 (en) 2013-01-11 2017-06-13 Becton, Dickinson And Company Low-cost point-of-care assay device
US9797899B2 (en) 2013-11-06 2017-10-24 Becton, Dickinson And Company Microfluidic devices, and methods of making and using the same
US10018640B2 (en) 2013-11-13 2018-07-10 Becton, Dickinson And Company Optical imaging system and methods for using the same
WO2018230575A1 (en) * 2017-06-15 2018-12-20 オリンパス株式会社 Microscope system
US10438356B2 (en) 2014-07-24 2019-10-08 University Health Network Collection and analysis of data for diagnostic purposes
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
EP1660870A2 (en) 2003-08-26 2006-05-31 Blueshift Biotechnologies, Inc. Time dependent fluorescence measurements
EP1784255A1 (en) 2004-05-13 2007-05-16 3M Innovative Properties Company Ablated predetermined surface geometric shaped boundary formed on porous material mounted on a substrate and methods of making same
EP1774024A4 (en) 2004-07-02 2012-04-04 Blueshift Biotechnologies Inc Exploring fluorophore microenvironments
US7615369B2 (en) * 2004-09-22 2009-11-10 The Regents Of The University Of Michigan Reconfigurable protein patterning using electrowetting microelectrodes
US20060166305A1 (en) * 2005-01-27 2006-07-27 Genetix Limited Animal cell confluence detection method and apparatus
US20060275852A1 (en) 2005-06-06 2006-12-07 Montagu Jean I Assays based on liquid flow over arrays
JP4538746B2 (en) 2005-09-21 2010-09-08 横河電機株式会社 Biochip and analyzer
EP1801593A1 (en) * 2005-12-22 2007-06-27 Philips Electronics N.V. A method of imaging biological specimens using inorganic nanoparticles as label agents
EP1989531A4 (en) * 2006-02-15 2013-10-16 Li Cor Inc Fluorescence filtering system and method for molecular imaging
US7923054B2 (en) 2006-04-19 2011-04-12 Gore Enterprise Holdings, Inc. Functional porous substrates for attaching biomolecules
EP2153211A4 (en) * 2007-05-02 2012-03-14 Fluidyx Pty Ltd A portable device for reading a fluorescent-labelled, membrane based array
US20090075828A1 (en) * 2007-09-17 2009-03-19 Gentel Biosurfaces, Inc. Integrated protein chip assay
EP2336776B1 (en) * 2008-08-29 2014-03-05 Actherm Inc. Liquid test strip
WO2010121643A1 (en) * 2009-04-20 2010-10-28 Agilent Technologies, Inc. Identifying calibration markers in multiple detection channels
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
US9315857B2 (en) 2009-12-15 2016-04-19 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse label-tags
US8809810B2 (en) 2010-05-20 2014-08-19 Honeywell International Inc. Microarray reader based on evanescent wave detection
JP2011017721A (en) * 2010-09-24 2011-01-27 Yokogawa Electric Corp Device and method for measuring luminous energy
CN102121898A (en) * 2011-01-19 2011-07-13 云南烟草科学研究院 Near-infrared sample detection device
ITTO20110567A1 (en) 2011-06-28 2012-12-29 St Microelectronics Srl Cartridge for biochemical analysis, for biochemical analysis system and method for performing a biochemical process
CN102927953B (en) * 2012-11-08 2015-06-10 西南石油大学 Test method for hydraulics size of shear flow polymer and test device thereof
EP3480321A1 (en) 2013-08-28 2019-05-08 Becton, Dickinson and Company Massively parallel single cell analysis
EP3055676A1 (en) * 2013-10-07 2016-08-17 Cellular Research, Inc. Methods and systems for digitally counting features on arrays
US9541750B2 (en) 2014-06-23 2017-01-10 Li-Cor, Inc. Telecentric, wide-field fluorescence scanning systems and methods
US20170107470A1 (en) * 2014-06-26 2017-04-20 The Trustees Of The University Of Pennsylvania Micro-fabricated multi-well chips for long term automated imaging of c. elegans growth and behavior
US9727810B2 (en) 2015-02-27 2017-08-08 Cellular Research, Inc. Spatially addressable molecular barcoding
CA2997627A1 (en) * 2015-10-15 2017-04-20 Planet Intellectual Property Enterprises Pty Ltd Device for reading an ivd assay
US10301677B2 (en) 2016-05-25 2019-05-28 Cellular Research, Inc. Normalization of nucleic acid libraries
US10202641B2 (en) 2016-05-31 2019-02-12 Cellular Research, Inc. Error correction in amplification of samples
EP3510379A1 (en) * 2016-09-08 2019-07-17 PreSens - Precision Sensing GmbH Method for calibrated optical measurement and system therefor
CA3034924A1 (en) 2016-09-26 2018-03-29 Cellular Research, Inc. Measurement of protein expression using reagents with barcoded oligonucleotide sequences
GB2571743A (en) * 2018-03-07 2019-09-11 Pop Bio Ltd A method of capturing image data of a luminescent sample and apparatus for the same
US3013467A (en) 1957-11-07 1961-12-19 Minsky Marvin Microscopy apparatus
JPS61152700A (en) * 1984-12-26 1986-07-11 Shionogi & Co Ltd Membrane supporting immobilized protein
JPH0814582B2 (en) * 1986-02-20 1996-02-14 富士写真フイルム株式会社 Immune reaction is quantitative for the multi-layered analysis element
JPH079087Y2 (en) * 1987-04-13 1995-03-06 大日本印刷株式会社 Inspection sheet - door
JPS645486A (en) * 1987-06-29 1989-01-10 Hitachi Ltd Cell culture method and apparatus therefor
JPH01240188A (en) * 1988-03-18 1989-09-25 Fuji Photo Film Co Ltd Functional organic thin film
US5720928A (en) * 1988-09-15 1998-02-24 New York University Image processing and analysis of individual nucleic acid molecules
EP0366241A3 (en) * 1988-10-04 1990-05-23 Fisher Scientific Company Device with adsorbent surface and method
US5491097A (en) * 1989-06-15 1996-02-13 Biocircuits Corporation Analyte detection with multilayered bioelectronic conductivity sensors
AU6513790A (en) † 1989-09-18 1991-04-18 Biostar Medical Products, Inc. Apparatus for detection of an immobilized analyte
JP2869866B2 (en) * 1989-10-06 1999-03-10 ティーディーケイ株式会社 Container for electrical chemiluminescence detection
US5096668A (en) * 1990-04-26 1992-03-17 Difco Laboratories Diagnostic test slide
DE69320484D1 (en) * 1992-09-14 1998-09-24 Stanford Res Inst Int anregungstecniken "up-converting" reporter molecule for biological and other testing methods using laser
US5552272A (en) * 1993-06-10 1996-09-03 Biostar, Inc. Detection of an analyte by fluorescence using a thin film optical device
JP3144513B2 (en) * 1993-06-17 2001-03-12 富士写真フイルム株式会社 Fluorescence microscope
US5784162A (en) * 1993-08-18 1998-07-21 Applied Spectral Imaging Ltd. Spectral bio-imaging methods for biological research, medical diagnostics and therapy
US6207369B1 (en) * 1995-03-10 2001-03-27 Meso Scale Technologies, Llc Multi-array, multi-specific electrochemiluminescence testing
WO1996028538A1 (en) * 1995-03-10 1996-09-19 Meso Scale Technologies, Llc Multi-array, multi-specific electrochemiluminescence testing
US6017496A (en) * 1995-06-07 2000-01-25 Irori Matrices with memories and uses thereof
JPH0943147A (en) * 1995-07-28 1997-02-14 Bunshi Bio Photonics Kenkyusho:Kk Dark-field vertical illuminating type fluorescene microscope device
US6165798A (en) * 1996-10-10 2000-12-26 University Of British Columbia Optical quantification of analytes in membranes
JP2003521670A (en) * 1997-10-31 2003-07-15 エルジェイエル・バイオシステムズ・インコーポレーテッド Apparatus and method for measuring the fluorescence polarization
US6294327B1 (en) * 1997-09-08 2001-09-25 Affymetrix, Inc. Apparatus and method for detecting samples labeled with material having strong light scattering properties, using reflection mode light and diffuse scattering
US6269846B1 (en) 1998-01-13 2001-08-07 Genetic Microsystems, Inc. Depositing fluid specimens on substrates, resulting ordered arrays, techniques for deposition of arrays
JPH11218690A (en) * 1998-02-04 1999-08-10 Olympus Optical Co Ltd Microscope with vertical fluorescent illuminating optical system
US6185030B1 (en) 1998-03-20 2001-02-06 James W. Overbeck Wide field of view and high speed scanning microscopy
US6406921B1 (en) * 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6197599B1 (en) 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
JP2002531470A (en) * 1998-12-01 2002-09-24 シントリクス バイオチップ, インコーポレイテッド Methods and compositions for performing an array of chemical reactions on a support surface
US6951682B1 (en) * 1998-12-01 2005-10-04 Syntrix Biochip, Inc. Porous coatings bearing ligand arrays and use thereof
JP2001215181A (en) * 2000-02-01 2001-08-10 Fuji Photo Film Co Ltd Polymeric supports for microscopic observation
CA2399163A1 (en) * 2000-02-18 2001-08-23 Isaac Rothman Composite membranes for assaying biomolecules
DE60035127T2 (en) * 2000-03-06 2008-02-14 Dade Behring Marburg Gmbh Polysaccharide-coated carrier, their manufacture and use
AU5945501A (en) * 2000-05-04 2001-11-12 Blood Res Center Colloid compositions for solid phase biomolecular analytical, preparative and identification systems
JP2001235473A (en) * 2000-09-21 2001-08-31 Biostar Inc Device for detecting immobilized analyte
AU1440402A (en) * 2000-10-26 2002-05-06 Glaucus Proteomics B V Products with biofunctional coating
US6905816B2 (en) * 2000-11-27 2005-06-14 Intelligent Medical Devices, Inc. Clinically intelligent diagnostic devices and methods
WO2002057416A2 (en) * 2000-12-12 2002-07-25 Autogenomics, Inc. Improved biochip
US6505921B2 (en) * 2000-12-28 2003-01-14 Eastman Kodak Company Ink jet apparatus having amplified asymmetric heating drop deflection
JP2002214232A (en) * 2001-01-12 2002-07-31 Toray Ind Inc Selectively-bonding-substance-fixed film and method for measuring substance to be tested using the same
US6573051B2 (en) * 2001-03-09 2003-06-03 Molecular Staging, Inc. Open circle probes with intramolecular stem structures
EP2582191B1 (en) † 2006-11-03 2018-03-07 Huawei Technologies Co., Ltd. Mobile communication method, mobile communication system and access entity
2003-08-18 AU AU2003269968A patent/AU2003269968A1/en not_active Abandoned
2003-08-18 WO PCT/US2003/025702 patent/WO2004017374A2/en not_active Application Discontinuation
2003-08-18 EP EP03751862.8A patent/EP1546721B2/en not_active Expired - Fee Related
JP2013050457A (en) * 2006-01-04 2013-03-14 Fujirebio America Inc Use of he4 and other biochemical markers for assessment of ovarian cancer
US10073093B2 (en) 2013-11-06 2018-09-11 Becton, Dickinson And Company Microfluidic devices, and methods of making and using the same
EP1955102B1 (en) 2013-04-24 Confocal imaging methods and apparatus
US7277569B2 (en) 2007-10-02 Apparatus and method for detecting and locating rare cells
US7272252B2 (en) 2007-09-18 Automated system for combining bright field and fluorescent microscopy
CN101900668B (en) 2012-05-16 Sample tube handling apparatus
US9677993B2 (en) 2017-06-13 Systems and methods for sample use maximization
EP0440342B1 (en) 1996-07-24 Laser excited confocol microscope fluorescence scanner and method
US6471916B1 (en) 2002-10-29 Apparatus and method for calibration of a microarray scanning system
US9194859B2 (en) 2015-11-24 Reader devices for optical and electrochemical test devices
KR100618502B1 (en) 2006-09-01 System and method of focusing electromagnetic radiation for use in a confocal microscopy imaging system
CA2299325C (en) 2008-01-08 A digital imaging system for assays in well plates, gels and blots
US6441379B1 (en) 2002-08-27 Imaging system for an optical scanner
EP1912740B1 (en) 2016-04-27 Optical assay system
US7170597B1 (en) 2007-01-30 Microplate reader
US6704104B2 (en) 2004-03-09 Multi-wavelength array reader for biological assay
CN102016546B (en) 2014-01-08 Compensator for multiple surface imaging
CN100356163C (en) 2007-12-19 Digital imaging system for assays in well plate, gels and blots
EP1347285B1 (en) 2007-05-30 Method and apparatus for measuring fluorescence luminance
US20030215791A1 (en) 2003-11-20 Method of and system for multiplexed analysis by spectral imaging
US20070207513A1 (en) 2007-09-06 Methods, Products, and Kits for Identifying an Analyte in a Sample
EP1599597B1 (en) 2010-08-04 Translucent solid matrix assay device for microarray analysis
DE69815121T2 (en) 2004-07-22 Optical substrate for improved fluorescence detection
EP0962772A2 (en) 1999-12-08 Improvements of biological assays for analyte detection
AU760425B2 (en) 2003-05-15 Method and measuring device for determining a plurality of analytes in a sample
US7081954B2 (en) 2006-07-25 Microarray detector and synthesizer
JP4864088B2 (en) 2012-01-25 Grating-based sensor and sensor readout system combining binding detection and fluorescence amplification without labeling


The seeds of the MPS Advocacy Support Service so acclaimed today were sown over 30 years ago when the Trustees recognised that befriending and information whilst important were not going to make the difference needed for families of children; and young adults suffering from these devastating life-limiting diseases. From a single advocacy officer, back in 1986 funded by BBC Children in Need, covering the whole of the UK, the Society's highly skilled advocacy team is now five strong and supporting over 1200 families and individuals in all aspects of social care as well as access to special educational needs and clinical management.
MPS, Fabry and related lysosomal storage diseases are complex conditions requiring considerable specialist management and treatment. In 1988, the Society helped to establish the first specialist team dedicated to the clinical management and treatment at the Royal Manchester Children's Hospital led by Prof Ed Wraith with a grant of over £120,000. With this investment the MPS specialist outreach clinics were born. Families and individuals living with MPS no longer faced arduous journeys to Manchester; linking up with metabolic doctors in Belfast, Glasgow, Cardiff, Newcastle, Birmingham, Norfolk and Bristol families could see the Manchester team closer to home. Over the last 30 years, the MPS Society has invested over £2 million in the NHS to improve clinical care for babies born in the UK who will develop and be diagnosed with these life threatening and devastating diseases. Today the MPS Society is a member of NHS England's Expert Advisory Group for Lysosomal Storage Diseases and works with health commissioners and government to set national standards on clinical care and treatment for those with MPS, Fabry and related Lysosomal Storage Diseases across the UK.
Learning from the MPS Society members' experience of participating in two early clinical trials for enzyme replacement, in 2006 the MPS Society launched its 'Clinical Trial Patient Access Programme'. The key objectives of this programme, which has been embraced by clinicians and the pharmaceutical industry alike, are to provide enhanced logistical support, including organising disability sensitive accommodation and travel; and timely reimbursement of expenses. Since 2006 the MPS Society has supported children and adults and their families on eight studies of durations of up to four years at five specialist centres in England. Whilst the majority of patients come from all corners of the UK and Europe others have travelled from South Africa and Australia. The MPS Society currently supports over 70 LSD children and adults on clinical trials in the UK, Europe and the rest of the world.
The MPS Society Registry is an on-going database that tracks demographic data, treatment options, some natural history data and patient reported outcomes (PROMS) from over 1200 MPS children and adults. It was initiated by the founding Board of the MPS Society over thirty years ago and as visionary as this decision was, little could the then Trustees have foreseen how valuable this MPS Registry would prove decades later. In the last 13 years with enzyme replacement therapy being clinically trialled and considered for marketing approval for MPS I, MPS II, MPS IVA and MPS VI the MPS registry has presented the most complete data set available worldwide. Whilst there are now product registries for Fabry, MPS I, MPS II and MPS VI the MPS Registry continues to serve the MPS community whether it be informing patients about clinical trial and focus group opportunities; supporting the pharmaceutical industry in clinical trial development undertaking PROMS ; and advising Healthcare Commissioners on patient cohorts.
In 1990 the MPS Society hosted an International Symposium on Mucopolysaccharide Diseases at the University of Manchester Institute of Science and Technology. Over 600 patients, their families, clinicians, researchers and scientists participated in this three day meeting that boasted a comprehensive, volunteer led children's activity programme to enable parents to attend the symposium. This initiative was embraced by the MPS International Network of MPS Support Groups which was established by the UK MPS Society in 1984. This meeting continues to be held every two years around the world and in 2002 the UK MPS Society co-organised this meeting in Paris with the French LSD patient organisation, Vaincre les Maladies.
One of the significant achievements of the MPS Society is using all its learning, experiences and tools to work collaboratively with a great number of agencies in the voluntary and statutory sector and at a governmental level. In April 2005 the highly specialised service for Lysosomal Storage Diseases was nationally designated by the Department of Health. This came about after eighteen months of lobbying by MPS members and the MPS Society in tandem with its advocacy team supporting families to appeal decisions by Primary Care Trusts not to prescribe life-saving enzyme replacement therapy and taking two decisions to judicial view. Achieving the nationally designated service which includes clinical management and treatment was not only good news for UK MPS patients but continues to influence decisions in Europe and beyond. Not complacent in 2012 when the New NHS Commissioning Board was introduced and the Advisory Group for Nationally Specialised Services was to be disbanded the MPS Society supported over 400 member families to set out their concerns to the Prime Minister, Deputy Prime Minister and their Members of Parliament. Certain reassurances by Government were received that confirmed funding of enzyme replacement therapy would not be affected by the introduction of NHS England and the Health and Social Care Act 2013.
The MPS Society funds world-class pioneering research that may translate into potential treatments or cures for children and adults with MPS, Fabry and related Lysosomal Diseases. But is not all about money. In 1988 responding to the need to find the X-linked gene that causes MPSII disease the MPS Society teamed up with Professor John Hopwood from Adelaide Women's and Children's Hospital. At the MPS National Conference Weekend at the Post House Hotel, Heathrow over 50 boys with Hunter disease and their mothers gave a small sample of blood. Eighteen months later and 10,000 miles away Prof Hopwood found the same complete gene deletion (a missing gene) in the blood of two of the boys. Thanks to Christopher Shorthouse and Robert Culley and all the others who gave their time and blood Prof Hopwood found the Hunter gene and published his findings for the benefit of the global academic community.
Recognising there is considerable research strength in working in partnership the MPS Society with funding of over £1.5 million in 2006 established of the MPS Stem Cell Research Group following the appointment of Dr Brian Bigger. The objectives of the Group are to focus further on understanding the mechanisms of disease pathology in Mucopolysaccharidosis (MPS), development of more effective diagnostic tools for these diseases, and bringing about a generation of novel and clinically relevant therapeutic approaches to curing these diseases. This has included examining the potential of defined stem cell subsets from bone marrow to repopulate organs that are difficult to treat in MPS, such as the brain and bones.
The risks of haematopoietic stem cell transplantation (HSCT) to the MPSI Hurler patient are high due to the immune responses between the donor and patient cells so the Group are developing immunomodulators and T regulatory cells to achieve transplant tolerance using less severe chemotherapy. As HSCTs are not always successful first time, the Group have also been investigating the mechanisms of cell engraftment in MPS and how They can improve stem cell homing and engraftment.
The Group has gone from strength to strength. Following the publication of preclinical data in the mouse model of Sanfilippo disease IIIB (MPS IIIB) showing significant delay in neurodegeneration and behavioural correction following high daily doses of the drug genistein aglycone delivered over a 9 month period the MPS Society currently has an appeal to fund a placebo controlled clinical trial using high doses of pharmaceutical grade genistein aglycone in 30 patients with MPS IIIA, B and C in Manchester.
Progress is being made into the use of Gene Therapy as Sanfilippo (MPS III) mice are receiving their first gene therapy injections. The project entitled Long-Term Intracerebral AAV-hHGSNAT delivery in MPS IIIC mice is being led by Brian Bigger based at Manchester University and Alexey Pshezhetsky of Sainte Justine's Children's Hospital, Montreal. Dr Bigger has also recently developed a stem cell gene therapy treatment for MPS IIIA that it is hoped to bring to the clinic in 2016.


text:
Q: Printing Interface library in cmake How to print the interface library in cmake. Actually i want to do this for a debugging purpose.
so want to know how to print what are all the include directories in that interface library
I have a interface library A which is linked to 2 interface libraries B and C(i.e A includes B and C).
Now i want to know whether A contains all the paths are not..how to check that?

redpajama_set_name: RedPajamaStackExchange